Stem cell therapy trial aims to halt vision loss in dry AMD
Disease control
Recruiting now
This early-stage trial tests whether transplanting special stem cells into the eye is safe for people with dry age-related macular degeneration (AMD), a leading cause of vision loss. About 18 adults over 55 with dry AMD will receive the cell transplant during eye surgery. The mai…
Phase: PHASE1, PHASE2 • Sponsor: Luxa Biotechnology, LLC • Aim: Disease control
Last updated May 15, 2026 11:56 UTC